Background Thrombin activatable fibrinolysis (TAFI) is a glycoprotein that inhibits fibrinolysis. Pro-TAFI is cleaved by Factor IIa – Thrombomodulin complex, producing actived TAFI (TAFI:Ac).
Pregnancy is a hypercoaguable state associated with increased levels of pro-coagulant factors; enhanced thrombin generation and impaired fibrinolysis.
TAFI may contribute to the decreased fibrinolysis seen in pregnancy.
Currently there are conflicting reports on TAFI antigen (TAFI:Ag) levels in pregnancy and no data on the dynamic changes in levels and activity during pregnancy and its correlation with adverse pregnancy outcome.
Method Consecutive TAFI:Ag and activity (TAFI:Ac) levels were measured during the first, second and third trimester in 80 women.
All participants in the study had no co-morbidities and had an uncomplicated singleton pregnancy.
Results TAFI:Ag levels significantly increased with gestation peaking in the third trimester with mean levels of 120, 139 and 148 μg/ml in the first, second and third trimesters respectively (p<0.035).
TAFI:Ac levels significantly increased between the first and second trimesters with mean values of 47 and 52 μg/ml respectively (p<0.01). TAFI:Ac levels then plateaued in the third trimester (with a mean value of 53 μg/ml).
Conclusion TAFI antigen and activity levels are increased in normal pregnancy
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.